FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

AIM: To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma. METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Gastroenterol
Autors principals: Guion-Dusserre, Jean-Florian, Lorgis, Veronique, Vincent, Julie, Bengrine, Leila, Ghiringhelli, Francois
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Inc 2015
Matèries:
Retrospective Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326145/
https://ncbi.nlm.nih.gov/pubmed/25717243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i7.2096
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars